Spelling out cancer on the nanoscale

Nano-fluidic system reads oncoprotein levels from tiny samples

Tumors start small and stay quiet, yet their intentions are clearly spelled out internally, if we could only read them. No matter how small, every tumor reveals its identity in tiny amounts of abnormally expressed proteins called oncoproteins. Being able to read trace oncoprotein levels from early-stage tumors would speak volumes to physicians and cancer researchers. Enter nano-fluidics and the art of reading a lot from very little.

Researchers led by Dean Felsher at Stanford University School of Medicine, and bioengineers at Cell Biosciences in Palo Alto, collaborated to develop an automated, high-throughput, nano-fluidic system that was able to measure the levels of three oncoproteins: MYC, BCL2, and AKT, in tiny samples drawn as very fine needle aspirates from hematopoetic tumor cells in preclinical transgenic mouse models. The nano-fluidic system physically separates the proteins in very small capillary tubes and then uses antibodies for protein detection. It was also tested on human lymphoma samples.

In previous work, the Felsher group had shown that inactivating MYC induces sustained tumor regression in mice. The researchers decided to test their conditional model of MYC-induced lymphoma by using their nano-fluidic system to quickly measure the impact of targeted protein inhibitors in mice. A series of fine needle-aspirated samples was analyzed, confirming a decrease in oncoprotein levels.

The new nano-fluidic system was also tested on human tumors by measuring the levels of MYC, BCL2, ERK, and AKT proteins in the lymph nodes obtained from patients with Burkitt’s, mantle cell, or follicular lymphoma. The nano-fluidic system reported that MYC was overexpressed in Burkitt’s, while BCL2 was overexpressed in mantle cell and follicular lymphoma patients. In parallel, traditional Western blots were performed to confirm BCL-2 and MYC levels.

"Our strategy can be used to repetitively and quickly assess the levels of oncoproteins in cancer cells grown in the laboratory and in human patients," says Felsher. "It may prove useful for the early detection of cancer, and for monitoring patients’ responses during their treatment, allowing clinicians to tailor treatments to individual patients. Finally, we provide a high throughput method to identify if new cancer drugs are effective at targeting specific oncoproteins."

###

News from
The American Society for Cell Biology
46th Annual Meeting
San Diego, CA
December 9–3, 2006

EMBARGOED
FOR RELEASE
10:00 am, U.S. Pacific Time
Wednesday, December 13, 2006

Contact
Dean Felsher
Division of Oncology
Stanford University School of Medicine
269 Campus Drive
CCSR 1105
Stanford, CA 94305
dfelsher@stanford.edu
Phone: (650) 725-6454

Debrabrita Deb-Basu
Cell Biosciences
1050 Page Mill Road
Palo Alto, CA 94305
ddeb-basu@cellbiosciences.com
Phone: (650) 859-1977

Author presents
Wednesday, Dec. 13
1:30 pm–3:00 pm
Session 441
Cancer IV
Presentation 2672
Poster Board B602
Halls C–G

Measurement of Oncoproteins in Preclinical and Clinical Specimens Using a Nano-fluidic High Throughput Approach

D. Deb-Basu,1 Alice Fan, 2 D. Voehringer,1 J. Ferrante,1 A. Bhamidipati,1 J. Gossett,1 R. O'Neill,1 D. Felsher2
1Cell Biosciences, Palo Alto, CA, 2Stanford University School of Medicine, Stanford, CA


Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
    Published on PsychCentral.com. All rights reserved.

 

 

It's so hard when I have to, and so easy when I want to.
-- Annie Gottlier